Article of the Week, Suggested by the BPDCN International Registry

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the Week Suggested by the BPDCN International Registry-Astghik Voskanyan

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting

The Armenian BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) Register likely refers to a specialized database or registry in Armenia focused on collecting, analyzing, and managing data related to BPDCN, a rare and aggressive form of blood cancer. This kind of registry would be crucial for gathering epidemiological data, understanding disease prevalence in the Armenian population, monitoring treatment outcomes, and potentially guiding research and clinical practice in managing BPDCN.

We are pleased to announce that the BPDCN team’s original abstract has been published on the Cancer Network site, a specialized online platform that provides information, resources, and support related to cancer. The abstract presents a case of a patient diagnosed with BPDCN, highlighting key challenges, treatment approaches, and diagnostic criteria associated with the disease.

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting

Authors: Nerses Ghahramanyan, Elen Baloyan, Gevorg Tamamyan, Fiza Khan, Foorquan Hashmi, Naveen Pemmaraju, Astghik Voskanyan, Marina Konopleva.

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.